A new macrolide antibiotic, desmycosin, has been prepared by chemical modification of desmycosin. In vitro, against selected animal bacterial pathogens, it inhibited growth of Pasteurella multocida, Pasteurella haemolytica, Mycoplasmahyopneumoniae, Actinobacillus pleuropneumoniae, Streptococcus suis, Actinomyces pyogenes and certain other bacteria at levels of 6.25^g/ml or less. In general, the MICsfor Gram-negative enteric bacteria have been >50^g/ml. Concentrations equivalent to 4 x the MICvalue were bactericidal for Pasteurella sp. EL-870 had other antibacterial properties whichwerecharacteristic of macrolideantibiotics.
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EL-870 was selected from a large number of derivatives of desmycosin obtained by chemical modification of the C-20 aldehyde2) for further evaluation to determine its potential for therapeutic use in animals. Selection was based upon in vitro antibacterial activity, the prevention of mortality when tested by parenteral and oral administration in day-old chicks challenged with Pasteurella multocida and other criteria related to chemical syntheses. EL-870 is one of a small group of desmycosin derivatives with in vitro activity equivalent to desmycosin but with activity superior to desmycosin when administered orally for the treatment of pasteurellosis in chicks.
The in vitro antibacterial activity of EL-870 against selected animal bacterial pathogens and certain other antibacterial properties of the compound are reported in this paper. Special emphasis was given to the determination of the sensitivity of Pasteurella sp. to EL-870 due to the importance of these bacteria as pathogens in respiratory diseases of animals.
Materials and Methods

EL-870
The chemical structure of EL-870, 20-deoxo-20-(3,5-dimethylpiperidin-l-yl)desmycosin, is shown in Fig. 1 . Desmycosin is readily produced from tylosin by mild acid hydrolysis to remove the terminal sugar mycarose. EL-870 is prepared from desmycosin by reductive amination of the C-20 aldehyde with a mixture of cis and /ra/w-3,5-dimethylpiperidine.
EL-870 used for the in vitro studies in this paper, except for the compoundsused in the comparison of the antibacterial activity of the cis and the trans isomers, was 75^80% pure and consisted of approximately 85% cis to 15% trans. The trans isomer is an approximate 1 : 1 mixture of diastereomers. Chromatography on silica gel, [elution with MeOH-CH2C12 -NH4OH(49.5 : 49.5 : 1)], furnished fractions which were predominantly cis (>95 : 5) or trans (16 : 84) for the side-by-side comparative study. EL-870 was used as the free base in these studies.
Bacterial Isolates
Eighty-five of the Pasteurella sp. isolates tested had been isolated from the respiratory tract of cattle at veterinary diagnostic laboratories located in Texas, Oklahoma or Arizona during a period Presented previously in part: See ref 1. Most of these 95 were resistant to more than one antibacterial agent. This resistance was reported to be plasmid derived and included penicillin, tetracycline, ampicillin, streptomycin and sulfonamides3). Six of the porcine P. multocida isolates were toxigenic Carter4) capsular serotype D, while the remainder were Carter serotype A isolates. All other bacterial isolates had been collected from infected animals over a period of several years. Antibacterial Activity and Properties Most MICvalues were determined by standard microtiter or tube broth-dilution tests using Mueller-Hinton broth (Gibco Labs.). The agar dilution test procedure was used with a few of the bacteria. With certain of the bacteria, appropriate enrichment media were required. Cultures of the isolates were diluted, dependent upon the species, so that the inoculum contained 103 to 105 colony forming units (cfu) per well. For most of the bacteria, incubation was at 37°C for 18~20 hours. Similar test procedures were used with selected bacteria to compare the antibacterial activity of the cis and trans isomers of EL-870 and to test erythromycin and tylosin-resistant isolates for sensitivity toEL-870.
Effect of Certain Factors on the MIC
To determine the effect of EL-870 concentration on possible in vitro bactericidal activity of EL-870, three isolates of P. multocida and three of P. haemolytica were used to inoculate Mueller-Hinton broth containing EL-870 at concentrations equal to 1 x, 2x and 4x the MICvalue vs. each of the bacteria. Initial bacterial concentration was 105 cfu/ml. Samples were collected after incubation at 37°C for 0, 2, 4 and 20 hours, and ten-fold dilutions were plated using duplicate Tryptose agar plates. Colonies on these plates were counted after 20 hours' incubation at 37°C.
In vitro development of bacterial resistance to EL-870 was measured using isolates of P. multocida, P. haemolytica or Actinomycespyogenes. These organisms were passaged daily for 15 days in MuellerHinton broth which contained two-fold dilutions of EL-870. Inoculum for each successive test was taken from the highest concentration of EL-870 in which growth had occurred in the preceding test. The MICwas recorded daily.
The effect of pH on the antibacterial activity of EL-870 was appraised by determination of the MICfor isolates of Pasteurella sp. and A. pyogenes in Mueller-Hinton media with the pH adjusted to 7.0 or 8.0. Various inoculum dilutions of the same bacterial cultures were tested using Mueller-Hinton broth to determine the effect of inoculum size on the MIC. The influence of serum or plasma on the MIC vs. these same bacteria was also determined. Freshly-collected, filter-sterilized serum or plasma, obtained from individual calves or pigs which had not received antimicrobial treatment, was mixed in equal volumes with Mueller-Hinton medium. MICvalues in the media with serum or plasma were compared to the MICin mediumonly.
Results
In Vitro Antibacterial Activity The in vitro antibacterial activity of EL-870 (see in Table 1 ) was primarily against certain Gramnegative and Gram-positive bacteria, anaerobes and Mycoplasma sp. The majority of the Gramnegative enteric bacteria were not sensitive to EL-870. The activity against Actinobacillus pleuropneumoniaewas somewhat surprising, since these bacteria are not usually sensitive to macrolide antibiotics. All 29 A. pleuropneumoniae isolates tested were sensitive. As indicated in the table, resistant isolates of certain species normally sensitive to EL-870 have been found.
The MIC95 of EL-870 for P. multocida isolates was 6.25^g/ml (Table 2) . Ninety-five % of the P. haemolytica isolates were inhibited by 3.12^g/ml. All of the P. haemolytica isolates with known plasmid mediated multiple antibacterial resistance were sensitive to EL-870 at a level of 3.12 g/ml. There were no effects on the MIC of EL-870 based upon Pasteurella serotype. Sensitivity 
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MICvalues for the three isolates tested were 6.25, 3.12 and 1.56 jug/ml.
EL-870 concentrations of 1 x (å ), 2x (å¡)or4x (à") the MIC value. O: Control.
to EL-870 of the recent clinical isolates of P. haemolytica and P. multocida was similar to that of the older isolates. Species origin of P. multocida isolates did not appear to affect the MIC. The MICfor EL-870 cisand trans isomers was the same for 6/14 of the bacterial isolates tested (Table 3) . With the other eight isolates, the MIC for the cis isomer was one dilution lower than that of the trans. The in vitro activity of the isomers was not markedly different. Selected isolates of Mycoplasmagallisepticum, A. pyogenes and P. multocida resistant to tylosin and erythromycin were also resistant to EL-870. Concentrations of EL-870 in the growth medium of P. haemolytica at 1 x or 2 x the MIClevel resulted in slight reductions in cfu's after 2, 4 or 20 hours' incubation ( Fig. 2) . At 4 x the MIC concentration, EL-870 was bactericidal after 20 hours' incubation. Results were similar with P. multocida isolates.
Fifteen consecutive passages of bacteria in broth containing sub-lethal concentrations of EL-870 resulted in a gradual* slight to moderate increase in the MIC. For example, with three isolates of P. haemolytica, the mean initial MIC was 1.3^g/ml, while at the 15th passage, the new MIC was 5.2. Similar values for three isolates of A. pyogenes were 0.012 and 0.024.
A reduction in pH of the test medium from 8.0 to 7.0 resulted in a one to eight-fold decrease in the MICof EL-870 for the 12 bacteria evaluated which is typical for macrolide antibiotics. With Pasteurella sp., an increase in the inoculum of 104 cfu resulted in a zero to four-fold increase in the MICof EL-870. Similar findings occurred with A. pyogenes. The MICof EL-870 was not increased or was increased by a factor of only two, when determined in the presence of 50% bovine or porcine serum or plasma. Serum binding is not marked with EL-870. Discussion EL-870, a new macrolide antibiotic has been found to have an antimicrobial spectrum characteristic of macrolide antibiotics.
In addition, EL-870 had significant activity in vitro against A. pleuropneumoniae. This activity has been demonstrated in our laboratory in pigs challenged in- FEB. 1987 tranasally with A. pleuropneumoniae and treated parenterally with EL-870. It is especially active against isolates of P. multocida and P. haemolytica. Only 2/257 Pasteurella isolates tested had MICs of >25^g/ml. These results are indicative of the potential for use of EL-870 as a treatment of pasteurellosis in animals. The finding that a level of EL-870 equivalent to 4 x the MICis bactericidal for Pasteurella sp. after 20 hours' incubation, suggests that this compoundcould exhibit bactericidal in vivo activity against these bacteria. The possibility of this occurring would be enhanced if EL-870 is found to concentrate in lung tissue in a fashion similar to certain other macrolide antibiotics5). Studies in progress, which will be described in later publications, demonstrate the effectiveness of EL-870 as a treatment in cattle with naturally occurring pasteurellosis. Development of EL-870 for the treatment of respiratory disease in animals appears feasible, but will be dependent upon the results of target animal efficacy tests, toxicological testing, tissue residue studies and other factors.
